Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Curevac Ag patents


Recent patent applications related to Curevac Ag. Curevac Ag is listed as an Agent/Assignee. Note: Curevac Ag may have other listings under different names/spellings. We're not affiliated with Curevac Ag, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Curevac Ag-related inventors


Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. ... Curevac Ag

Method for adding cap structures to rna using immobilized enzymes

The present invention relates to an immobilized capping enzyme, preferably an immobilized vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2′-o-methyltransferase, preferably an immobilized vaccinia virus cap-specific nucleoside 2′-o-methyltransferase. ... Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)i;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

Method for producing rna compositions

The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one rna and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. ... Curevac Ag

Injection solution for rna

The invention relates to the use of rna and an aqueous injection buffer containing a sodium salt, a calcium salt and optionally a potassium salt and optionally lactate, in the preparation of a rna injection solution for increasing rna transfer and/or rna translation into/in a host organism. The invention relates further to a rna injection solution and to a method for increasing the rna transfer and/or rna translation of rna in vivo and in vitro.. ... Curevac Ag

Method for in vitro transcription using an immobilized restriction enzyme

The present invention relates to a method for in vitro transcription of a linear template dna which is produced using an immobilized restriction endonuclease. The invention also relates to mutated restriction enzymes which are suitable for immobilization and a solid support to which these restriction enzymes are immobilized. ... Curevac Ag

Rna containing composition for treatment of tumor diseases

The present invention relates to rna containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the rna containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.. . ... Curevac Ag

Method of producing rna from circular dna and corresponding template dna

The present invention is concerned with a method of producing a target rna using a circular dna, wherein said method does not comprise a step of linearizing said circular dna. The present invention further relates to a circular dna comprising an rna polymerase promoter sequence, followed by a sequence encoding a target rna, followed by a sequence encoding a self-cleaving ribozyme, followed by an rna polymerase terminator sequence element, wherein the latter element may comprise several rna polymerase terminator sequences. ... Curevac Ag

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. ... Curevac Ag

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. ... Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. ... Curevac Ag

Combination of vaccination and inhibition of the pd-1 pathway

The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. ... Curevac Ag

06/21/18 / #20180169201

Combination of vaccination and inhibition of the pd-1 pathway

The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. ... Curevac Ag

06/14/18 / #20180161457

Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

The present invention is directed to an inventive polymeric carrier molecule according to generic formula (i) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.. ... Curevac Ag

06/14/18 / #20180161454

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(orn)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

06/14/18 / #20180161453

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

06/14/18 / #20180161452

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

06/14/18 / #20180161451

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

06/14/18 / #20180161422

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. ... Curevac Ag

05/31/18 / #20180148727

Artificial nucleic acid molecules

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-utr element) and/or at least one 5′-untranslated region element (5′-utr element), wherein the at least one 3′-utr element and/or the at least one 5′-utr element prolongs and/or increases protein production from said artificial nucleic acid molecule and wherein the at least one 3′-utr element and/or the at least one 5′-utr element is derived from a stable mrna. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. ... Curevac Ag

05/31/18 / #20180147146

Dry powder composition comprising long-chain rna

The present invention is directed to a storage-stable formulation of long-chain rna. In particular, the invention concerns a dry powder composition comprising a long-chain rna molecule. ... Curevac Ag

05/24/18 / #20180142275

Immobilized poly(n)polymerase

The present invention relates to an immobilized poly(n)polymerase (pnp), methods of producing said pnp and uses thereof. Further disclosed is an enzyme reactor and kit comprising the pnp for producing polynucleotidylated ribonucleic acid poly(n)rna)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.. ... Curevac Ag

05/10/18 / #20180126005

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l; (lys)m; (his)n; (orn)o; (xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

05/10/18 / #20180126003

New targets for rna therapeutics

The present invention relates to a method for treating or preventing a disease, disorder or condition by administration of a polynucleotide, e.g. A modified rna, encoding a peptide or protein related to this disease, disorder or condition. ... Curevac Ag

05/10/18 / #20180125952

Prime-boost regimens involving administration of at least one mrna construct

The present invention relates to prime-boost regimens that involve the administration of at least one mrna construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen. ... Curevac Ag

05/03/18 / #20180117179

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

03/22/18 / #20180078629

Combination of vaccination and inhibition of mhc class i restricted antigen presentation

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (mhc) class i restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. ... Curevac Ag

03/01/18 / #20180055952

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein

The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. ... Curevac Ag

02/15/18 / #20180044687

Artificial nucleic acid molecules for improved protein expression

The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-utr comprising at least one poly(a) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-utr comprising at least one poly(a) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. ... Curevac Ag

11/16/17 / #20170326225

Ebolavirus and marburgvirus vaccines

The present invention relates to an mrna sequence, comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (gp) and/or the matrix protein 40 (vp40) and/or the nucleoprotein (np) of a virus of the genus ebolavirus or marburgvirus or a fragment, variant or derivative thereof. Additionally, the present invention relates to a composition comprising a plurality of mrna sequences comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (gp) and/or the matrix protein 40 (vp40) and/or the nucleoprotein (np) of a virus of the genus ebolavirus or marburgvirus or a fragment, variant or derivative thereof. ... Curevac Ag

09/21/17 / #20170266268

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.. ... Curevac Ag

09/07/17 / #20170252430

Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. ... Curevac Ag

08/31/17 / #20170247699

Artificial nucleic acid molecules for improved protein or peptide expression

The invention relates to an artificial nucleic acid molecule comprising at least one 5′utr element which is derived from a top gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. ... Curevac Ag

08/24/17 / #20170239372

Reversible immobilization and/or controlled relase of nucleic acid containing nanoparticles by (biodegradable) polymer coatings

The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. ... Curevac Ag

08/03/17 / #20170218030

Respiratory syncytial virus (rsv) vaccine

The present invention relates to an mrna sequence, comprising a coding region, encoding at least one antigenic peptide or protein of rsv infections respiratory syncytial virus (rsv) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mrna sequences comprising a coding region, encoding at least one antigenic peptide or protein of rsv infections respiratory syncytial virus (rsv) or a fragment, variant or derivative thereof. ... Curevac Ag

07/27/17 / #20170211068

Immunostimulation by chemically modified rna

The present invention relates to an immunostimulating agent comprising at least one chemically modified rna. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. ... Curevac Ag

07/20/17 / #20170202957

Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine. ... Curevac Ag

07/13/17 / #20170196969

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.. ... Curevac Ag

07/13/17 / #20170196967

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. ... Curevac Ag

06/29/17 / #20170182150

Vaccination with mrna-coded antigens

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.. ... Curevac Ag

06/29/17 / #20170182081

Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids

The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of rna and mrna. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. ... Curevac Ag

05/11/17 / #20170128549

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

04/27/17 / #20170114378

Methods and means for enhancing rna production

The present invention relates to a method for synthesizing an rna molecule of a given sequence, comprising the step of determining the fraction (1) for each of the four nucleotides g, a, c and u in said rna molecule, and the step of synthesizing said rna molecule by in vitro transcription in a sequence-optimized reaction mix, wherein said sequence-optimized reaction mix comprises the four ribonucleoside triphosphates gtp, atp, ctp and utp, wherein the fraction (2) of each of the four ribonucleoside triphosphates in the sequence-optimized reaction mix corresponds to the fraction (1) of the respective nucleotide in said rna molecule, a buffer, a dna template, and an rna polymerase. Further, the present invention relates to a bioreactor (1) for synthesizing rna molecules of a given sequence, the bioreactor (1) having a reaction module (2) for carrying out in vitro rna transcription reactions in a sequence-optimized reaction mix, a capture module (3) for temporarily capturing the transcribed rna molecules, and a control module (4) for controlling the infeed of components of the sequence-optimized reaction mix into the reaction module (2), wherein the reaction module (2) comprises a filtration membrane (21) for separating nucleotides from the reaction mix, and the control of the infeed of components of the sequence-optimized reaction mix by the control module (4) is based on a measured concentration of separated nucleotides.. ... Curevac Ag

03/09/17 / #20170065727

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag

03/02/17 / #20170056529

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. ... Curevac Ag

02/02/17 / #20170029847

Artificial nucleic acid molecules

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-utr) element comprising a nucleic acid sequence which is derived from the 3′-utr of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. ... Curevac Ag

02/02/17 / #20170028059

Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates

The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such a composition or vaccine composition and to the second medical use of such a composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein. ... Curevac Ag

01/19/17 / #20170014496

Combination of vaccination and ox40 agonists

The present invention relates to a vaccine/agonist combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one ox40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. ... Curevac Ag

01/05/17 / #20170000871

Composition for treating prostate cancer (pca)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna preferably an mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), and steap (six transmembrane epithelial antigen of the prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. ... Curevac Ag

01/05/17 / #20170000870

Combination therapy for immunostimulation

The present invention relates to a method for immunostimulation in a mammal which comprises a. Administration of at least one mrna containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. ... Curevac Ag

01/05/17 / #20170000858

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(orn)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Ag








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Curevac Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Curevac Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###